ATE464051T1 - Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz - Google Patents
Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienzInfo
- Publication number
- ATE464051T1 ATE464051T1 AT02711903T AT02711903T ATE464051T1 AT E464051 T1 ATE464051 T1 AT E464051T1 AT 02711903 T AT02711903 T AT 02711903T AT 02711903 T AT02711903 T AT 02711903T AT E464051 T1 ATE464051 T1 AT E464051T1
- Authority
- AT
- Austria
- Prior art keywords
- combination
- heart failure
- levosimendan
- treatment
- calcium source
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229910052791 calcium Inorganic materials 0.000 title abstract 2
- 239000011575 calcium Substances 0.000 title abstract 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title abstract 2
- 229960000692 levosimendan Drugs 0.000 title abstract 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 229910001424 calcium ion Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20010233A FI20010233A0 (fi) | 2001-02-08 | 2001-02-08 | Menetelmä sydämen vajaatoiminnan hoitoon |
| PCT/FI2002/000099 WO2002062342A1 (en) | 2001-02-08 | 2002-02-08 | A method for the treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464051T1 true ATE464051T1 (de) | 2010-04-15 |
Family
ID=8560270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02711903T ATE464051T1 (de) | 2001-02-08 | 2002-02-08 | Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7279479B2 (de) |
| EP (1) | EP1363636B1 (de) |
| JP (1) | JP4320175B2 (de) |
| AT (1) | ATE464051T1 (de) |
| CA (1) | CA2437196C (de) |
| DE (1) | DE60235965D1 (de) |
| ES (1) | ES2343060T3 (de) |
| FI (1) | FI20010233A0 (de) |
| WO (1) | WO2002062342A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103429234B (zh) | 2010-12-10 | 2016-10-05 | 布罗迪健康科学有限公司 | 茉莉酮酸酯治疗膀胱功能障碍的用途 |
| AU2018273105B2 (en) * | 2017-05-24 | 2023-08-10 | Dsrco Bv | Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745130A (en) * | 1978-04-24 | 1988-05-17 | Massachusetts Institute Of Technology | Composition for increasing blood pressure |
| DK172690B1 (da) * | 1981-10-22 | 1999-05-31 | Tanabe Seiyaku Co | Analogifremgangsmåde til fremstilling af salte af sulfodehydroabietinsyre eller hydrater deraf |
| US4971982A (en) * | 1987-07-06 | 1990-11-20 | Hoffmann-La Roche Inc. | Benzopyran derivatives |
| CA2020073A1 (en) | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
| EP0421441B1 (de) * | 1989-10-06 | 1995-01-25 | Fujirebio Inc. | Pantothensäure Derivate |
| GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| US6448248B1 (en) | 1996-12-18 | 2002-09-10 | Abbott Laboratories | Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists |
| WO1998050048A1 (en) * | 1997-05-07 | 1998-11-12 | Pharma Mar, S.A. | Aplidine as an l-type calcium channel enhancer |
| US5998458A (en) * | 1997-06-25 | 1999-12-07 | University Technology Corporation | Method of treating heart failure |
| US6030288A (en) * | 1997-09-02 | 2000-02-29 | Quixotic Solutions Inc. | Apparatus and process for verifying honest gaming transactions over a communications network |
| FI973804A7 (fi) * | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
| FI980902A7 (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
| FI981473L (fi) | 1998-06-25 | 1999-12-26 | Orion Yhtymae Oyj | Menetelmä pulmonaalihypertension hoitamiseksi |
| FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
| WO2001028548A1 (en) * | 1999-10-19 | 2001-04-26 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
-
2001
- 2001-02-08 FI FI20010233A patent/FI20010233A0/fi unknown
-
2002
- 2002-02-08 ES ES02711903T patent/ES2343060T3/es not_active Expired - Lifetime
- 2002-02-08 AT AT02711903T patent/ATE464051T1/de not_active IP Right Cessation
- 2002-02-08 CA CA2437196A patent/CA2437196C/en not_active Expired - Fee Related
- 2002-02-08 DE DE60235965T patent/DE60235965D1/de not_active Expired - Lifetime
- 2002-02-08 JP JP2002562349A patent/JP4320175B2/ja not_active Expired - Fee Related
- 2002-02-08 EP EP02711903A patent/EP1363636B1/de not_active Expired - Lifetime
- 2002-02-08 WO PCT/FI2002/000099 patent/WO2002062342A1/en not_active Ceased
- 2002-02-08 US US10/467,459 patent/US7279479B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2437196A1 (en) | 2002-08-15 |
| ES2343060T3 (es) | 2010-07-22 |
| JP4320175B2 (ja) | 2009-08-26 |
| FI20010233A0 (fi) | 2001-02-08 |
| DE60235965D1 (de) | 2010-05-27 |
| CA2437196C (en) | 2010-10-19 |
| US20040092523A1 (en) | 2004-05-13 |
| EP1363636A1 (de) | 2003-11-26 |
| WO2002062342A1 (en) | 2002-08-15 |
| US7279479B2 (en) | 2007-10-09 |
| EP1363636B1 (de) | 2010-04-14 |
| JP2004518698A (ja) | 2004-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116463T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| DE60143911D1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| DK0796103T3 (da) | Anvendelse af røgelse til behandling af Alzheimer-sygdommen | |
| NO20000446D0 (no) | Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser | |
| TW202617146A (zh) | 包含靶向ｖａｖ１的降解劑的組合 | |
| PL1656131T3 (pl) | Zastosowanie betainy w leczeniu chromania przestankowego | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
| DK1478362T3 (da) | Kombinationsbehandling til akut myokardisk infarkt | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| DE60235965D1 (de) | Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| BG105434A (bg) | Сертралинов орален концентрат | |
| NO20052999L (no) | Ny synergistisk kombinasjon omfattende roflumilast og formoterol | |
| SE0102887D0 (sv) | New formulation | |
| RU2004112422A (ru) | Роувастатин в преддеменционных состояниях | |
| DE60111622D1 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
| BR0316059A (pt) | Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise | |
| BR9913242A (pt) | Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono | |
| DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
| WO2000002578A8 (fr) | Remedes contre les maladies liees a l'apoptose | |
| NO20043774L (no) | The use of devazenide as analgesic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |